Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bank of Montreal (BMO) vs Sana Biotechnology Inc (SANA) Price & Performance

Bank of MontrealTrade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

Bank of Montreal vs Sana Biotechnology Inc — how do they compare? Bank of Montreal trades at $183.22 (market cap $126.83B), while Sana Biotechnology Inc trades at $3.78 (market cap $1.13B). The key difference: Bank of Montreal is far larger — about 112.2× Sana Biotechnology Inc's market cap, and Bank of Montreal pays a 2.69% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.

BMOSANA
Market Cap
$126.83B$1.13B
Sector
FinancialsHealth
52-Week High
$183.65$5.92
52-Week Low
$112.54$2.68
Dividend Yield
2.69%
Enterprise Value
$1.05B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bank of Montreal

BMO trades at $181.91, up 0.2% today, with a bullish technical signal from moving averages and support near $181. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.68 exceeding the $2.54 estimate. Revenue grew to $36.10B in 2025, and net income margin improved to 24.12%. Recent news includes the sale of Moneris for $1.44B and the launch of new ETNs with REX Shares.

Outlook is supported by consistent earnings performance and strategic initiatives, but risks include interest rate sensitivity and macroeconomic pressures. Analysts are divided with a Hold consensus, reflecting balanced optimism and caution. The stock's valuation at a P/E of 19.41 appears reasonable given profitability trends.

Sana Biotechnology Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

About Bank of Montreal

Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.

Read more on BMO

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA